1Ano·

Immunic with "Strong Buy"

Immunic has a consensus rating of "Strong Buy" based on 4 Buy predictions, 0 Hold predictions and 0 Sell predictions. What is the Immunic price target? The average price target for Immunic is 6.33. This is based on 12-month price targets published by 4 Wall Street analysts in the last 3 months.

I had already pointed this out early on at $atai 1 year ago at 0.75 euros 😬

17 Comentários

Chris@Multibagger

1Ano

First on the watch list.

•

Raketentoni@Raketentoni

1Ano

@Multibagger also take a look at A3EEZB

•

Chris@Multibagger

1Ano

@Raketentoni has also ended up there. What do you (not the analysts) see as the 6-12 month targets for both? And why did $PSTV have such a dramatic fall? Failed pipeline candidates?

•

Raketentoni@Raketentoni

1Ano

@Multibagger Yes, but that was a long time ago. Now the therapy approaches look better. It's just a gamble 🤷 but hey, 500 shares in everyone's portfolio and good

•

Chris@Multibagger

1Ano

@Raketentoni why didn't you suggest it to me yesterday, I was just about to buy it and it's 30% higher? Why?

••

Raketentoni@Raketentoni

1Ano

@Multibagger well the train hasn't left yet 😬 I got in at 0.41 dollars

••

Raketentoni@Raketentoni

8Mês

@Multibagger I hope you are in?

The analyst update didn't come out of nowhere. It was in response to data Immunic presented at the ACTRIMS Forum (a major MS convention) over the weekend (Feb. 5-7):
The drug: vidofludimus calcium (their lead candidate).
The data: In the phase 2 study (CALLIPER), they showed that the drug not only reduces inflammation in the brain, but also reduces the reactivation of the Epstein-Barr virus (EBV). This is currently a "hot topic" scientifically, as EBV is considered one of the main triggers for MS.
The delay: With small caps, it often takes 1-2 days for such specialist data to be "digested" by the broad market - or for an analyst to translate it into a catchy price target. This is exactly what happened today.
The message: The analyst firm H.C. Wainwright has confirmed its buy recommendation ("Buy").
The price target: The analyst (Matthew Caufield) has left the target at USD 8.00.

•

Chris@Multibagger

8Mês

@Raketentoni not yet. I just can't always be there. $NKTR was enough

•

Raketentoni@Raketentoni

7Mês

@Multibagger I hope you were inside? 😂

•

Chris@Multibagger

7Mês

@Raketentoni Where do you mean now?